New vaccine combo shows promise in advanced cancers
Disease control
Completed
This phase 2 trial tested a new cancer vaccine (IO102-IO103) combined with the immunotherapy drug pembrolizumab as a first treatment for people with advanced lung, head/neck, or bladder cancer that had spread. The study enrolled 63 participants to see if the combination is safe a…
Phase: PHASE2 • Sponsor: IO Biotech • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC